Naltrexone
- Generic Name
- Naltrexone
- Brand Names
- Contrave, Embeda, Vivitrol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23NO4
- CAS Number
- 16590-41-3
- Unique Ingredient Identifier
- 5S6W795CQM
- Background
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
- Indication
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
- Associated Conditions
- Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
- Associated Therapies
- -
Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 43
- Registration Number
- NCT03854942
- Locations
- 🇩🇪
University Hospital RWTH Aachen, Aachen, Germany
Evaluation of Intranasal Naltrexone and Naloxone
- Conditions
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 12
- Registration Number
- NCT03851731
Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Sassani, Joseph S., MD, MHA
- Target Recruit Count
- 60
- Registration Number
- NCT03660475
- Locations
- 🇺🇸
Total Eye Care, Memphis, Tennessee, United States
Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- South West Sydney Local Health District
- Target Recruit Count
- 180
- Registration Number
- NCT03479086
- Locations
- 🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 86
- Registration Number
- NCT03431831
- Locations
- 🇺🇸
Regional West Medical Center-University of Nebraska Medical Center, Scottsbluff, Nebraska, United States
🇺🇸Regional West Physicians Clinic, Scottsbluff, Nebraska, United States
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03232346
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT03132571
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03113409
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Low Dose Naltrexone for Chronic Pain From Arthritis
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 29
- Registration Number
- NCT03008590
- Locations
- 🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
Immune Effects of Low-dose Naltrexone in ME/CFS
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT02965768
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.